Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04956692 |
|---|---|
| Brief Title: | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) |
| First Submitted : | July 6, 2021 |
| First Submitted that Met QC Criteria : | July 6, 2021 |
| First Posted : | July 9, 2021 |
| Results First Submitted : | March 27, 2024 |
| Results First Posted with QC Comments : | April 23, 2024 |
| Results First Submitted that Met QC Criteria : | May 9, 2024 |
| Results First Posted : | May 20, 2024 (Estimate) |
| Last Update Submitted that Met QC Criteria : | May 9, 2024 |
| Last Update Posted : | May 20, 2024 (Estimate) |